Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Gordon Cook, Christopher Parrish, MBBChir, MRCP, FRCPath, MA, PhD, Kwee Yong, PhD, Jamie Cavenagh, MD PhD, John A Snowden, MD, Mark T Drayson, Mamta Garg, David Cairns, John Ashcroft, Alina Striha, Anna Hockaday, Ruth M De Tute, BSc,MSc, Roger G. Owen, Cathy Williams, Mark Cook, MBChB,PhD

Blood (2018) 132 (Supplement 1): 255.

https://doi.org/10.1182/blood-2018-99-112116

Published: 2018

Journal Articles

Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

Joanne Sowter, MSc, Dimitrios A Koutoukidis, PhD, Maggie Heinrich, PhD, Orla McCourt, MSc, Allan Hackshaw, Rebecca Beeken, PhD, Dunnya De-Silva, Stephanie Philpott, MSc, Ali Rismani, MBBS, Neil K Rabin, MD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD, Charalampia Kyriakou, MD PhD, Atul Mehta, FRCP, Bruce Paton, PhD, Abigail Fisher, PhD, Kwee Yong, PhD

Blood (2018) 132 (Supplement 1): 974.

https://doi.org/10.1182/blood-2018-99-111403

Published: 2018

Journal Articles

Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients

Mark T Drayson, MD PhD, Stella Bowcock, MDMA, Tim Planche, MDPhD, Gulnaz Iqbal, PhD, Jill Wood, MPH, Kerry Raynes, MSc, Guy Pratt, MD FRCP, FRCPath, Kwee Yong, PhD, Peter Hawkey, FRCPath, Helen Higgins, MSc, Janet Dunn, PhD

Blood (2017) 130 (Supplement 1): 903.

https://doi.org/10.1182/blood.V130.Suppl_1.903.903

Published: 2017

Journal Articles

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

Suzanne Trudel, MD FRCP(C), Nikoletta Lendvai, MD PhD, Rakesh Popat, MD PhD, Peter M. Voorhees, MD, Brandi Reeves, MD, Edward N. Libby, III, MD, Paul G Richardson, MD, Larry Anderson, MD PhD, Heather Sutherland, MD, Kwee Yong, PhD, Axel Hoos, MD PhD, Michele Gorczyca, MS, Soumi Lahiri, PhD, Zangdong He, PhD, Roxanne C Jewell, PhD, Joanna B. Opalinska, MD PhD, Adam D. Cohen, MD

Blood (2017) 130 (Supplement 1): 741.

https://doi.org/10.1182/blood.V130.Suppl_1.741.741

Published: 2017

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Kwee Yong, PhD, Samantha Hinsley, Holger W. Auner, MD PhD, Debbie Sherratt, Ruth Mary De Tute, BSc,MSc, Sarah Brown, Louise Flanagan, Cathy Williams, Jamie Cavenagh, Martin F Kaiser, MD, Neil Rabin, Karthik Ramasamy, Mamta Garg, MD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Gareth J. Morgan, MD PhD, Faith E. Davies, MD, Roger G Owen, MD

Blood (2017) 130 (Supplement 1): 835.

https://doi.org/10.1182/blood.V130.Suppl_1.835.835

Published: 2017

Journal Articles

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Blood (2017) 130 (Supplement 1): 267.

https://doi.org/10.1182/blood.V130.Suppl_1.267.267

Published: 2017

Journal Articles

Assessment of Anti-Bacterial Antibodies in Multiple Myeloma Patients at Disease Presentation and in Response to Therapy: Implication for Patient Management

Ilaria Chicca, PhD, Jennifer LJ Heaney, PhD, Gulnaz Iqbal, PhD, Stella Bowcock, MDMA, Tim Planche, MDPhD, Jill Wood, MPH, Kerry Raynes, MSc, Peter Hawkey, FRCPath, Guy Pratt, MD FRCP, FRCPath, Kwee Yong, PhD, Helen Higgins, MSc, Janet Dunn, PhD, Mark T Drayson, MD PhD

Blood (2017) 130 (Supplement 1): 3036.

https://doi.org/10.1182/blood.V130.Suppl_1.3036.3036

Published: 2017

Journal Articles

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Blood (2017) 130 (Supplement 1): 1815.

https://doi.org/10.1182/blood.V130.Suppl_1.1815.1815

Published: 2017

Journal Articles

Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients

Stella Bowcock, MDMA, Catherine Atkin, MD, Gulnaz Iqbal, PhD, Tim Planche, MDPhD, Guy Pratt, MD FRCP, FRCPath, Kwee Yong, PhD, Jill Wood, MPH, Kerry Raynes, MSc, Eric Low, BSc, Helen Higgins, MSc, Janet Dunn, PhD, Mark T Drayson, MD PhD

Blood (2017) 130 (Supplement 1): 2132.

https://doi.org/10.1182/blood.V130.Suppl_1.2132.2132

Published: 2017

Journal Articles

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Blood (2017) 130 (Supplement 1): 1864.

https://doi.org/10.1182/blood.V130.Suppl_1.1864.1864

Published: 2017

Journal Articles

Clinical Benefit of Depth of Response for Relapsed/Refractory Multiple Myeloma Patients Treated on Clinical Trials: Retrospective Analysis from Two Tertiary Centres

Hian Li Esther Chan, Dunnya De-Silva, Rakesh Popat, MD PhD, Neil Rabin, Ashu Wechalekar, Sufyan Achhala, Adeline Lin, Wee Joo Chng, MB ChB, MRCP, PhD, Kwee Yong, PhD

Blood (2017) 130 (Supplement 1): 1825.

https://doi.org/10.1182/blood.V130.Suppl_1.1825.1825

Published: 2017

Journal Articles

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Blood (2011) 118 (21): 3976.

https://doi.org/10.1182/blood.V118.21.3976.3976

Published: 2011

Journal Articles

CD26 Inhibition Can Aid the Homing of Cytokine Activated Mobilized Peripheral Blood (MPB )CD34 + Cells to the Bone Marrow (BM) but a Ligand Dependent Attachment Defect Prevents Their Long Term Retention and Subsequent Engraftment

Konstantina Kallinikou, Fernando Anjos-Afonso, Michael P Blundell, Stuart J Ings, Deepika Kassen, PhD, Adrian J Thrasher, MD, PhD, David C Linch, MD FMedSci, Dominique Bonnet, PhD, Kwee Yong, PhD

Blood (2011) 118 (21): 141.

https://doi.org/10.1182/blood.V118.21.141.141

Published: 2011

Journal Articles

An Alternate Day Dosing Strategy for Lenalidomide in Multiple Myeloma Improves Cost-Effectiveness Whilst Maintaining Efficacy,

Rakesh Popat, Jenny Dickson, Iftekhar Khan, Simon Cheesman, Laura Percy, Sally Moore, Shirley D'Sa, MD, Neil Rabin, Kwee Yong, PhD

Blood (2011) 118 (21): 4201.

https://doi.org/10.1182/blood.V118.21.4201.4201

Published: 2011

Journal Articles

Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Inhibit Osteoclast Activation and Increase Trabecular Bone Area in a Xenogeneic Murine Model of Myeloma.

Neil Rabin, MD, Chara Kyriakou, MD, Reuben Benjamin, MD, Arnold Pizzey, Orla Gallagher, BSc, Nalini Singh, Clive Buckle, PhD, Peter Croucher, PhD, Amit Nathwani, PhD, Kwee Yong, PhD

Blood (2006) 108 (11): 505.

https://doi.org/10.1182/blood.V108.11.505.505

Published: 2006

Journal Articles

Differential Expression of CD180 and sIgM by B Chronic Lymphocytic Leukaemia Cells (B-CLL) Using Mutated and Unmutated IgVh Genes.

Nino Porakishvili, PhD, Nino Kulikova, PhD, Maria Manoussaka, PhD, Andrew P. Jewell, PhD, Pierre Y. Youinou, PhD, S. Nedelec, PhD, Kwee Yong, PhD, Amit Nathwani, MD, B. Heelan, PhD, Terry Hamblin, MD, P. Wallace, PhD, P. Ely, PhD, Ed Clarke, PhD, Peter M. Lydyard, PhD

Blood (2004) 104 (11): 2807.

https://doi.org/10.1182/blood.V104.11.2807.2807

Published: 2004

Journal Articles

Patients with Lymphoplasmacytic Lymphoma Can Be Salvaged with Autologous Stem Cell Transplantation, Irrespectively of the Number of Previous Treatment Lines. Analysis of 146 Cases from the European Bone Marrow Transplant Registry (EBMT).

Charalampia A. Kyriakou, MD, Anthony H. Goldstone, MD, Anna Sureda, MD, Kwee Yong, PhD, Shirley D’Sa, MD, Goli Taghipour, Carmen Ruiz de Elvira, David C. Linch, MD, PhD, Norbert Schmitz, MD, PhD

Blood (2004) 104 (11): 11.

https://doi.org/10.1182/blood.V104.11.11.11

Published: 2004

NARROW

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Assessment of Anti-Bacterial Antibodies in Multiple Myeloma Patients at Disease Presentation and in Response to Therapy: Implication for Patient Management

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Clinical Benefit of Depth of Response for Relapsed/Refractory Multiple Myeloma Patients Treated on Clinical Trials: Retrospective Analysis from Two Tertiary Centres

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

CD26 Inhibition Can Aid the Homing of Cytokine Activated Mobilized Peripheral Blood (MPB )CD34 + Cells to the Bone Marrow (BM) but a Ligand Dependent Attachment Defect Prevents Their Long Term Retention and Subsequent Engraftment

An Alternate Day Dosing Strategy for Lenalidomide in Multiple Myeloma Improves Cost-Effectiveness Whilst Maintaining Efficacy,

Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Inhibit Osteoclast Activation and Increase Trabecular Bone Area in a Xenogeneic Murine Model of Myeloma.

Differential Expression of CD180 and sIgM by B Chronic Lymphocytic Leukaemia Cells (B-CLL) Using Mutated and Unmutated IgVh Genes.

Patients with Lymphoplasmacytic Lymphoma Can Be Salvaged with Autologous Stem Cell Transplantation, Irrespectively of the Number of Previous Treatment Lines. Analysis of 146 Cases from the European Bone Marrow Transplant Registry (EBMT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only